Streetbeat News

Analyst Ratings

DXCM

Over the past three months, 6 analysts have provided ratings for DexCom (NASDAQ:DXCM), with recent updates showing a positive trend in sentiment and an increase in the 12-month price target to an average of $134.5, up from $120.33. Analysts from firms such as Raymond James, Piper Sandler, Wells Fargo, and Morgan Stanley have raised their price targets, reflecting optimism about DexCom's financial health, which includes strong revenue growth, net margin, ROE, and ROA, despite some concerns over debt management.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 1:00 pm

COIN

Coinbase Global, Inc. (NASDAQ:COIN) stock fell in premarket trading due to broader market sentiment and a cryptocurrency market sell-off after the SEC approved a Bitcoin ETF. Additionally, JPMorgan analysts downgraded Coinbase to Underweight, maintaining a $80 price target. Bitcoin's price dropped by 4.50%, trading below $39,000. Coinbase's premarket stock price decreased by 4.17% to $122.86.

Portfolio Pulse from Shanthi Rexaline

January 23, 2024 | 12:57 pm

CHRS

Truist Securities analyst Robyn Karnauskas has maintained a Buy rating on Coherus BioSciences (NASDAQ:CHRS) but reduced the price target from $12 to $8.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 12:53 pm

CHRS

Truist Securities analyst Robyn Karnauskas has maintained a Buy rating on Coherus BioSciences (NASDAQ:CHRS) but reduced the price target from $12 to $8.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 12:50 pm

DHI

Wedbush analyst Jay McCanless has reiterated a Neutral rating on D.R. Horton (NYSE:DHI) and maintained a price target of $115. The reaffirmation of the rating and price target suggests that Wedbush's outlook on D.R. Horton remains unchanged.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 12:49 pm

BNTX

CPE

CSTM

CVX

DSP

ENPH

MTRN

NS

TEVA

ZUO

Several top Wall Street analysts have updated their price targets and ratings for various US-listed companies. Notably, Truist Securities raised the price target for Enphase Energy, Inc. (ENPH) from $85 to $145 and upgraded the stock to Buy, implying over a 35% potential rally. Other companies such as Constellium SE (CSTM), Zuora, Inc. (ZUO), Teva Pharmaceutical (TEVA), NuStar Energy L.P. (NS), Callon Petroleum Company (CPE), BioNTech SE (BNTX), Viant Technology Inc. (DSP), Chevron Corporation (CVX), and Materion Corporation (MTRN) also saw changes in their price targets and ratings.

Portfolio Pulse from Avi Kapoor

January 23, 2024 | 12:44 pm

NEXN

Needham analyst Laura Martin has maintained a Buy rating on Nexxen International (NASDAQ:NEXN) and increased the price target from $5 to $6.5.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 12:40 pm

MANH

Rosenblatt analyst Blair Abernethy has maintained a Neutral rating on Manhattan Associates (NASDAQ:MANH) and increased the price target from $200 to $215.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 12:39 pm

INTC

Rosenblatt analyst Hans Mosesmann has reiterated a Sell rating on Intel Corporation (NASDAQ:INTC) and maintained a price target of $17. This reaffirmation of the Sell rating suggests that the analyst continues to have a bearish outlook on Intel's stock performance.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 12:36 pm

TXN

Rosenblatt analyst Hans Mosesmann has reiterated a Buy rating on Texas Instruments (NASDAQ:TXN) and maintained a price target of $190.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 12:29 pm